Already FDA-approved to treat major depression and migraines, TMS can now be marketed as a treatment for obsessive compulsive disorder Santa Barbara, Calif., September 21, 2018 – Transcranial Magnetic Stimulation (TMS) therapy is rapidly growing in popularity as a treatment [..]
The National Institute of Mental Health is currently recruiting participants for a clinical study to see if using functional magnetic resonance imaging (fMRI) to guide repetitive transcranial magnetic stimulation (rTMS) helps locate the best area for treatment and to explore whether the efficacy of such treatment can enhanced through cognitive behavioral therapy (CBT). Eligible participants are adults ages 18 to 65 with a major depressive disorder and current depression. The study is composed of three phases: Phase 1 will be 4 visits in 1 week where the fMRI will be done along with certain brain activity testing; Phase 2 will be conducted over 6 – 7 weeks where participants will do 30 TMS sessions combined with computer generated CBT and repeat the Phase 1 tests; and, Phase 3 will be 3 visits over three months to rate participants’ depression symptoms. A complete description of the study can be found at clinicaltrials.gov.